Immuron Ltd

IMC

Company Profile

  • Business description

    Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

  • Contact

    Chapman Street
    Unit 10, 25-37
    Blackburn North
    MelbourneVIC3130
    AUS

    T: +61 398245254

    https://www.immuron.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    7

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,637.8012.900.15%
CAC 407,842.7054.600.70%
DAX 4024,167.65129.460.54%
Dow JONES (US)42,098.70244.95-0.58%
FTSE 1008,720.475.54-0.06%
HKSE23,573.38315.071.35%
NASDAQ19,100.9498.22-0.51%
Nikkei 22538,432.98710.581.88%
NZX 50 Index12,281.3180.95-0.65%
S&P 5005,888.5532.99-0.56%
S&P/ASX 2008,409.8012.900.15%
SSE Composite Index3,363.4523.510.70%

Market Movers